Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | USP2 | O75604 | 5/20 | 0.51 |
| ▸ | HPGD | P15428 | 5/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19504703 | 0.89 | OPRM1 (0.47) | KDM4EALDH1A1CYP2C19MAPK1CYP1A2 | |
| SCHEMBL8330359 | 0.89 | USP2 (0.54) | KDM4EALDH1A1CYP2C19MAPK1CYP1A2 | |
| SCHEMBL18711889 | 0.88 | USP2 (0.49) | ALDH1A1CYP2C19MAPK1CYP1A2TDP1 | |
| SCHEMBL15632465 | 0.84 | CYP1A2 (0.62) | KDM4EALDH1A1CYP2C19MAPK1CYP1A2 | |
| SCHEMBL26783934 | 0.84 | USP2 (0.60) | KDM4EALDH1A1CYP2C19MAPK1CYP1A2 | |
| SCHEMBL20472810 | 0.83 | USP2 (0.47) | ALDH1A1CYP2C19MAPK1CYP2C9USP2 | |
| SCHEMBL18390599 | 0.83 | CYP1A2 (0.54) | KDM4EALDH1A1CYP2C19MAPK1CYP1A2 | |
| SCHEMBL15544126 | 0.81 | USP2 (0.58) | KDM4EALDH1A1CYP2C19MAPK1CYP1A2 | |
| SCHEMBL23763347 | 0.81 | CYP1A2 (0.52) | ALDH1A1CYP2C19MAPK1CYP1A2TDP1 | |
| SCHEMBL30499286 | 0.81 | USP2 (0.46) | ALDH1A1CYP2C19MAPK1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4223754-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-09 | — | — | EP | disclosed |
| WO-2023125707-A1 | P38 MAPK/MK2 PATHWAY REGULATOR, COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海美悦生物科技发展有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | X-CHEM GLOBAL HQ | 2023-06-29 | — | — | US | disclosed |
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | X-CHEM GLOBAL HQ | 2023-06-29 | — | — | US | disclosed |
| US-20230174487-A1 | PHENYLPROPIONAMIDE COMPOUND AND USE THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2023-06-08 | — | — | US | disclosed |
| WO-2023098656-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BEIGENE, LTD. (GB) | 2023-06-08 | — | — | WO | disclosed |
| WO-2021159993-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR ASSOCIATED KINASE (IRAK) /FMS-LIKE RECEPTOR TYROSINE KINASE (FLT3), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | PHARMABLOCK SCIENCES (NANJING) , INC. (CN) | 2021-08-19 | — | — | WO | disclosed |
| WO-2021136354-A1 | BIPHENYL DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2021-07-08 | — | — | WO | disclosed |
| EP-3377060-B1 | PYRAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF | LUNDBECK LA JOLLA RESEARCH CENTER INC (US) | 2020-08-19 | — | — | EP | disclosed |
| WO-2020037079-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2020-02-20 | — | — | WO | disclosed |
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-26 | — | — | US | disclosed |
| WO-2016044604-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, ADRM1, PRMT1 | KDM4E 892/4885ALDH1A1 1286/4885CYP2C19 3703/4885 |
| US-20230174487-A1 | PHENYLPROPIONAMIDE COMPOUND AND USE THEREOF | PAH, TRPV1, TRPA1 | KDM4E 2215/4885ALDH1A1 399/4885CYP2C19 79/4885 |
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1A, SCN3A, SCN2A | KDM4E 2085/4885ALDH1A1 1110/4885CYP2C19 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.